STTDAA | Synthesis of Truncated Tirandamycin A-D Derivatives as new Antihelminthic Agents

Summary
This project entitled “Synthesis of Truncated tirandamycin A-D derivatives as new Antihelminthic Agents (STTDAA)” aims at developing novel asparaginyl tRNA synthetase (AsnRS) inhibitors as potential antihelminthic agents, with new mechanisms of action for potential treatment of lymphatic filariasis (LF).
LF is one of the World Health Organization’s (WHO) top 10 neglected tropical diseases (NTDs), This incapacitating disease has infected over 200 million people in 73 tropical and subtropical countries, while more than 1.4 billion people remain at the risk of infection. Thus a top priority of the WHO is to search for new antihelminthic drugs that kill adult worms (macrofilaricides), have new mechanisms of action, and exhibit fewer side effects than currently available medications such as albendazole and ivermectin to which parasite resistance has already been confirmed.
To this end, two distinctively different but complimentary synthetic approaches towards tirandamycin A-D (TAMs A-D) derivatives, as AsnRS inhibitors will be developed. This will be followed by intensive structure activity relationship (SAR) studies, which will further promote improvements of the bioactivity and the drug characteristic of the synthesized derivatives. These studies will compose a vital part of a more comprehensive drug development program.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/661441
Start date: 01-06-2015
End date: 31-05-2017
Total budget - Public funding: 173 857,20 Euro - 173 857,00 Euro
Cordis data

Original description

This project entitled “Synthesis of Truncated tirandamycin A-D derivatives as new Antihelminthic Agents (STTDAA)” aims at developing novel asparaginyl tRNA synthetase (AsnRS) inhibitors as potential antihelminthic agents, with new mechanisms of action for potential treatment of lymphatic filariasis (LF).
LF is one of the World Health Organization’s (WHO) top 10 neglected tropical diseases (NTDs), This incapacitating disease has infected over 200 million people in 73 tropical and subtropical countries, while more than 1.4 billion people remain at the risk of infection. Thus a top priority of the WHO is to search for new antihelminthic drugs that kill adult worms (macrofilaricides), have new mechanisms of action, and exhibit fewer side effects than currently available medications such as albendazole and ivermectin to which parasite resistance has already been confirmed.
To this end, two distinctively different but complimentary synthetic approaches towards tirandamycin A-D (TAMs A-D) derivatives, as AsnRS inhibitors will be developed. This will be followed by intensive structure activity relationship (SAR) studies, which will further promote improvements of the bioactivity and the drug characteristic of the synthesized derivatives. These studies will compose a vital part of a more comprehensive drug development program.

Status

CLOSED

Call topic

MSCA-IF-2014-EF

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.2. Nurturing excellence by means of cross-border and cross-sector mobility
H2020-MSCA-IF-2014
MSCA-IF-2014-EF Marie Skłodowska-Curie Individual Fellowships (IF-EF)